Brief: Inotiv Q3 Adjusted EBITDA USD 11.6 Million

Inotiv

06/08/2025 21:05

Overview

Inotiv Q3 fiscal 2025 revenue rises 23.5% to $130.7 mln, beating expectations, per LSEG data

Adjusted EBITDA for Q3 fiscal 2025 beats estimates, reaching $11.6 mln

Company reports Q3 fiscal 2025 net loss of $17.6 mln

Result Drivers

RMS GROWTH - Revenue from Research Models & Services rose 34.1%, driven by increased NHP-related product and service revenue

DSA IMPROVEMENTS - Discovery & Safety Assessment revenue increased 8.9%, attributed to growth in general toxicology, biotherapeutic, and medical device services

INVESTMENT BENEFITS - Integration and optimization investments over the past two years have driven growth in quoting and awards, per CEO Robert Leasure Jr.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$130.70 mln
$127.10 mln (3 Analysts)
Q3 Net Income
-$17.60 mln
Q3 Adjusted EBITDA
Beat
$11.60 mln
$11 mln (3 Analysts)
Q3 Operating Income
-$5.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 58.5% above its August 5 closing price of $2.08

Press Release: ID:nGNX5x5Ykm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)